The Somatic Genomic Medicine Challenge
Genome encodes functional and dysfunctional information not only in its main chapters of linear sequences and primary chemical modifications such as methylations, also in its dynamic multi-dimensional structures, organizations, functional derivatives in forms of aberrant orders, binding and interactions, loops and folds, locations and shapes.
While linear sequences are coded in static bytes, real dynamic genomes function within a 4-dimensional framework in a 3D sphere less than 10 micrometers across, with many contact points. These complex interactions especially manifest in poly-aneuploidy genomes, chromothripsis, chromoplexy, large circular extrachromosome DNAs (ecDNA), and the chaotic genomic recycling and dumping grounds such as micronuclei and exosomes.
Within the much broader and complex epigenomic scope beyond primary methylation patterns, these previously under-defined yet highly medically relevant heterogenous real time somatic cell signals change the narratives of the inherited book of life as we age. This level of signals often got destroyed or altered during traditional destructive sample preparation for analysis (such as, mixing, sonication, fragmentation, structural folds or binding stripping). We should exam genomes with the context included.
About US
Dimension Genomics Inc is a post-seed stage startup dedicated to the development of new generation of sub-cellular and sub-nuclear single molecule level platform technology, targeting high dimension analysis in somatic cancer and aging cells.
Founded by a team of passionate tech entrepreneurs who have previous experience taking an original idea from Princeton University labs all the way to IPO and commercial products launch that changed how people assemble, study, understand linear genome and diagnose diseases.
For decades, we have been seeking the complete genome underlining the ultimate goal of precision and personalized medicine. There are roughly two types of genomic data, the relatively static inherited germline genome shared among the cells (the consensus); and the more dynamic individual somatic cell genomes changing throughout our life span (the baseline + deviations causing cancer and aging).
The majority of human sequencing data existing today are based on averaged consensus calls of millions of mixed cells and molecules as reduced or compressed representations of partial or under-phased "haploidy" genome (exomes, transcripts, or the "3-Billion-base genome").
The sample averaging "meatball" style data might be "ok-enough-approximation" of the diploid single zygote-derived inherited germline genome analysis, for reference, newborn, population survey, ancestry or common inherited disorder purpose. These "meatball" style data assumed majority data sets for AI training today.
In any given 7 ~ 37-trillion evolving somatic body cells, the ground truth could be from ~3.055-Billion (aneuploidy), ~6.2-Billion (diploid) to ~20-Billion plus nucleotides (poly-aneuploidy), for true medical grade analysis.
Cancer and degenerative aging diseases are inevitable consequences of somatic genomes' deterioration after a life-time error-prone genomic replications as cells divide and renew. Aneuploidy is a hallmark of cancer found in up to 90% of solid tumors, within which a critical subpopulation of poly-aneuploid cancer cells (PACCs) actively drives therapy resistance and disease progression. In cases of circular ecDNA-driven cancer relapses and drug-resistance development, they are present in as high as 60% of aggressive cancers such as brain tumors and Small Cell Lung Cancers (SCLCs).
Highly dynamic, complex and heterogenous somatic cell genome analysis in clinical context presents challenges for the legacy bulk solution sample consensus workflow developed for germline analysis, stagnates medical genomics transformation if continuing to bring a "Germline Analysis Knife" to a chaotic high-entropy "Somatic Genome Gun Fight".
Our Mission
With decades of unique experience in manipulating macromolecules within designed entropy-controlled microenvironments, we developed proprietary nanotech platform technologies that physically organize, enrich, and isolate targets at the level of single aberrant chromosome and its aberrant derivatives. Shown here, highly complex poly-aneuploidy cancer genomes with over 67 chromosomes, in addition to chromosomal derivatives and ecDNAs scattered in each cell, being physically organized and displayed on Dimension Chip for further loci and sequence-agnostic analysis and isolation.
This approach reveals the diluted or lost individual deleterious molecular deviations from the base germline signals, with highest signal clarity in somatic patient samples. These critical signals were often obfuscated in traditional sample preparation with cross-contamination by sample averaging across heterogeneous, rapidly evolving somatic cell populations.
Our discretely selective sample isolation and analysis technology will differentiate from the traditional bottom-up consensus tiling workflow as a top-down high-resolution Map-guided dissecting approach, with native context. This deconvolutes the lost "outliners" collapsed or abandoned by traditional algorithms, uncover foundational biomarkers in subclones of somatic cells at minimal residual level, with no a priori knowledge. We are ready to bring our 1st service offering to our partners and customers. The physically clean sample will cleanse and elevate high quality raw genomic data to be truly AI compatible and safe for medical use, with immediate clinical utility and market impact.
In the reality of personalized medicine, consensus is a hallucination. Precision and fidelity prevail over generative. When the stakes are life, as token prices continue to trend down, the unadulterated high quality raw genomic data is the sovereign.
For decades, we have been visiting genomic "steak house" but served "meatballs" and now fixed tissue "prosciutto", let's work together to keep expanding that menu.
Applications
Cancer Relapse and Drug Resistance Risk Assessment
Our ecDNA ecView Technology and Service allow us to provide precisely and efficiently full spectrum ecDNA profiles for translational research and recurring malignancy assessment for new and in-remission patients.
Companion Dx for Enhanced Trial Stratification
Over 90% oncology trials collapse and billions lost each year, not because drugs lacking activities, but often due to poor understanding of cancer biological heterogeneity. Aberrant genome + ecDNA profiling service screens cancer cell sample fitness and potential drug resistance assessment in patient stratification to improve better enrollment of candidates
Drug Discovery
Leveraging aberrant genome + ecDNA technology and database to provide service for translational research, preclinical drug discovery, uses advanced molecular modeling and artificial intelligence to identify novel drug targets and accelerate the development of life-saving therapies.
Precision Medicine
Our accessible bioinformatics expertise and software tools enable analysis and interpretation of complex genomics data, providing insights into disease mechanisms and new therapeutic targets.
Our personalized genomic and ecDNA profile information leverages genomic and clinical data to help physicians for individualized treatment plans reference and guidance, improving patient outcomes and quality of life.
The Future for Somatic Cancer Genomics is DISCRETE
Join Us in Transforming Precision Oncology and Genome Aging Management
From bulk averages to single-molecule precision through nanotechnology
- unlocking “hidden Drivers” in cancer relapses detection, monitoring, and treatment."
We are always looking for medical AI, translational, clinical application development partnerships
Dimension Genomics Inc San Diego, California
